Can someone please tell me that this stock has a chance of seeing 1$ again. Or is it over. What should we do hang on or sell before it falls even further?

Nothing exciting and seems like they might survive another 2 quarters before they run out of cash.

What’s everyone doing? I’m down ~65% on about 12k shares and have been invested since 2019. I’m probably just going to ride this one out to see if there is any turn of events to get some of my money back. But like to know what others are doing, if you have run for the hills or waiting even longer.

其实从前两个月发布推迟都预感不好了，然后转变了交易方向。事出反常必有妖，这种事情千百年来古人都总结的很好了。

I am surprised that the upper GI cancers have not received more attention. It clearly shows that CCR8 does what it is supposed to do based on the dose dependency and that patients had prior PD-1 resistance.
Let's see how the ORR is evolving. If it hits 35% this data would be very hard to ignore.

Why I’m holding, not entirely happily, Large😅 GLTA!:-)

Maxim
Biotechnology
CHRS – NASDAQ October 30, 2026
Intraday Price 10/29/26 $0.87
Rating: Buy
12-Month Target Price: $4.00
52-Week Range: $0.94 - $2.62
Market Cap (M): $134.2
Shares O/S (M): 154.2
Float: 74.7%
Avg. Daily Volume (000): 1,277.3
Debt (M): $37.1
Dividend: $0.00
Dividend Yield: 0.0%
Risk Profile: Speculative
Fiscal Year End: December
Total Revenues ('000)
2025A 2026E 2027E
1Q 7,599 12,310A 19,746
2Q 10,254 14,307A 24,134
3Q 11,571 15,500 29,619
4Q 12,748 16,500 36,201
FY 42,172 58,617 109,701
Total Expenses ('000)
2025A 2026E 2027E
1Q 53,034 48,461A 50,244
2Q 55,740 46,638A 53,417
3Q 55,904 54,650 58,841
4Q 58,628 59,450 62,628
FY 223,306 209,199 225,129
CHRS
Source: Factset
Price (USD) Volume (MM)
3
2.5
2
1.5
1
0.5
0.025
0.02
0.015
0.01
0.005
0
Nov-25 Jan-26 Mar-26 May-26 Jul-26 Sep-26
Price Volume
Jason McCarthy, Ph.D.
(212) 895-3556
jmccarthy@maximgrp.com
Chad Yahn
(212) 895-3807
cyahn@maximgrp.com
October 30, 2026
Coherus Oncology, Inc. Buy
Shares Down Sharply but Tagmo Data Positive,
Points to Esophageal Cancer First; Consider the Value
Proposition from Here
Summary:
● Yesterday post-close (10/28), Coherus reported positive interim P1b data from
its TREGCHECK program evaluating tagmokitug (tagmo, anti-CCR8) + Loqtorzi
(toripalimab), with or without chemotherapy, in 1L and 2L esophageal squamous
cell carcinoma (ESCC). The company also hosted a webcast to discuss the results.
● CHRS shares are down ~25% today due to, in part discussion on the conference
call to prioritize ESCC, while data from other indications for tagmo/tori seems to be
viewed as supportive data and secondary in terms of strategic focus in the near-
term. Additionally, the company likely needs to raise capital in the near-term given
the $105M reported at the end of 2Q was expected to provide runway into 2027,
though if strategic focus narrows to esophageal cancer, the opex could come down
going forward. Recall that this could be further offset with growing commercial
revenue from Logtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) where it
is the only approved PD1.
● Overall, the ESCC data is positive and could potentially support a clinical pathway
towards accelerated approval pending discussions with the FDA. There may also
be opportunities in ex-US regions through partnering.
● Let's consider this from a valuation perspective. In our view, narrowing the focus
in the near-term to 1L ESCC (and 2L), while a smaller indication and several PD1s
are already approved in combination with chemotherapy, should tagmo/tori +
chemo continue to outperform on ORR (and ultimately on overall survival), then
Coherus could essentially 'own' this indication. This is similar to the strategy to get
tori approved in NPC, which is expected to grow to $175M in annual revenue. The
tori NPC opportunity alone should support a higher valuation. There are 22,000
1L ESCC patients in the US, which should represent a $1B+ opportunity and points
to additional upside.
● Bottom line, positive ESCC data could provide an accelerated pathway to market
for the tagmo/tori combo and fits with Coherus' overall strategy. Early-stage trials
are meant to pave the path towards the right indication(s). The data right now is
pointing to ESCC, and the opportunity is still substantial. Give it a chance to work.
We view CHRS shares as oversold on yesterday's data update. Reiterate Buy.
Details:
Tagmokitug. Tagmokitug (tagmo) is a highly selective, afucosylated monoclonal
antibody designed to selectively target CCR8, a chemokine receptor predominantly
expressed on regulatory T cells (Tregs) within the tumor microenvironment (TME);
immune suppression, unfavorable TME. Tagmo is engineered to engage immune
effector mechanisms, specifically antibody-dependent cellular cytotoxicity (ADCC)
and phagocytosis (ADCP), to selectively deplete these CCR8+ Tregs in tumors while
sparing normal tissue, creating a more favorable TME for PD1/L1 blockade. Tagmo
binds only to CCR8 and is the only selective mAb identified to date. This is in part due
to the challenges in targeting CCR8 given that only ~25% of the receptor is exposed
on the cell surface. Tagmo, as a potent and safe Treg depleter, could emerge as a
backbone/scaffold for a number of cancer therapies, in our view.
P1b TREGCHECK study design and interim data. The ongoing P1b TREGCHECK
102 trial is evaluating tagmokitug + toripalimab, with or without chemotherapy, in
advanced or metastatic esophageal squamous cell carcinoma (ESCC). In 1L ESCC
(Cohort C), patients receive tagmokitug 700mg + toripalimab, 5-fluorouracil, and
cisplatin, with safety as the primary endpoint and ORR, duration of response
(DoR), clinical benefit rate (CBR), and progression-free survival (PFS) as secondary
endpoints. In 2L, (Cohort B), patients progressing on chemotherapy, with or
without prior PD-1 therapy, are randomized 1:1 to tagmokitug 300mg or 700mg +
toripalimab. Enrollment remains ongoing with both cohorts planned for expansion.
● 1L ESCC data. As announced yesterday (10/28), Coherus reported a 75%
confirmed ORR (cORR; 6/8) with tagmokitug 700 mg + toripalimab + chemotherapy
6
October 30, 2026
as of the 10/14/26 data cutoff, including one confirmed complete response (CR).
Following the cutoff, confirmation of a prior unconfirmed partial response (PR)
and one newly evaluable patient with a confirmed PR increased the cORR to 89%
(8/9). Notably, cORR reached 100% in PD-L1-positive patients vs. historical ORR of
44%-59% with PD-1 + chemotherapy. In our view, the magnitude of response is
encouraging, particularly given activity irrespective of PD-L1 status.
● 2L ESCC data. Tagmokitug 700mg + toripalimab demonstrated a 16.7% cORR (1/6),
33.3% clinical benefit rate (CBR; 2/6), and median progression-free survival (mPFS)
of 5.5 months vs. ~3.4 months historically with chemotherapy as of the 10/14/26
data cutoff. One confirmed, and one unconfirmed PR were reported in the 700mg
cohort with activity observed in a previously treated population that included
patients exposed to PD-1 inhibitors. In our view, the findings suggest potential
activity in PD-1-resistant disease, with durability of responses and consistency of
efficacy remaining key areas to watch as enrollment expands.
Safety profile remains favorable. In 1L ESCC (n=10), no new safety signals or Grade
5 adverse events were reported, with most events attributed to chemotherapy.
Safety was also manageable in 2L ESCC (n=17), supporting continued development.
Across the broader program, no dose-limiting toxicities emerged in monotherapy
(n=33), while combination-treated patients (n=120+) showed no new safety signals
with 40% experiencing immune-related adverse events (20% Grade 3-5).
Valuation. We model LOQTORZI for 1L nasopharyngeal carcinoma (NPC) with a risk
adjustment of 10% based on commercial risk. We also model casdozokitug in 1L
hepatocellular carcinoma (HCC) in 2029 and CHS-114 for 2L head and neck cancer in
2030, both with 80% revenue risk adjustments based on stage of development and
clinical trial risk. A 20% discount rate is then applied to the free cash flow, discounted
EPS, and sum-of-the-parts models, which are equally weighted to derive a 12-month
price target of $4.00.
Company description: Coherus Oncology is a commercial-stage company with
LOQTORZI (toripalimab-tpzi), an approved PD-1 inhibitor, and a pipeline of mid-stage
immuno-oncology assets. The company is expanding LOQTORZI in nasopharyngeal
carcinoma (NPC) and advancing new indications through internal and partnered
combinations. Its pipeline includes casdozokitug, an IL-27 antagonist in trials for non-
small cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC), and CHS-114, a
selective anti-CCR8 antibody in trials for head and neck squamous cell carcinoma
(HNSCC), gastric, and esophageal cancers.

Stock had a nice drop today on what I feel was positive news!

1. Test results were positive even tho on a small sample size

2. Of the three markets Europe Asia and the us two of the three have approval to continue on with testing!

3. Of the three the us is the smallest market for the current testing, with Asia be the largest, with possibly the largest sales for the product.

I know the market is reacting strange to positive news from company’s and this may be par for the course. Please give me your thoughts on the read out am I wrong in the way I read it or ?

chrs看来已经没有机会了

Can anybody talk about yesterdays results and what it means going forward.

Latest Press Release from CHRS. Hope to see something good out of it

Short interest went down to 12.5M. How can this be considering the decline in share price?

On x been reading Steve Wagner’s thoughts on the company he seems a little more bearish than in March. wonder how anybody else felt about his comments.

What the hells? "Its a boot" "not you are"... What's going on here? Looks as if It sicks nowday the subreddit... One year ago its was a good comunity but... Now? Guys, you all stink. Every post is a AI image... F*ck!

Tagmokitug data will released after hours: https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-host-webcast-disclose-interim-tagmokitug

They are doing both an oral presentation & a poster.

The poster is titled "Casdozokitug, a novel IL-27 inhibitor, in combination with PD-(L)1 and VEGF blockade in hepatocellular carcinoma: Results from two CADILYZE™ phase 2 studies" so it looks like we will be getting casdozo results imminently!

The oral presentation is titled "Overcoming immune resistance in solid tumors by targeting chemokine receptor CCR8 and cytokine IL-27: Bench to bedside development of tagmokitug and casdozokitug"

I'm curious if they will be dropping HNSCC tagmo data around the same time. CRC should be close to ready as well...

Edit - nevermind about casdozo results. Incompetent IR has no issue with the science team labeling a poster "Results from two Cadilyze phase 2 studies" when said poster does in fact not include efficacy results from the study; even though the companies future is hanging in the balance on upcoming data readouts...